Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032


On track to share interim Phase 1b data in H1 2024

...

Related Keywords

United States ,Japan ,California ,San Diego ,China ,Joseph Payne ,Linkedin ,Arcturus Therapeutics Holdings Inc ,Twitter ,Office Of Orphan Products Development ,Nasdaq ,Mrna Technology ,Drug Designation For The Company ,Drug Administration ,Arcturus Therapeutics Holdings ,Orphan Drug Designation ,Orphan Products Development ,Prescription Drug User Fee Act Application ,Drug Designation ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,